Atazanavir
- Generic Name
- Atazanavir
- Brand Names
- Evotaz, Reyataz, Atazanavir Krka, Atazanavir Viatris (previously Atazanavir Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C38H52N6O7
- CAS Number
- 198904-31-3
- Unique Ingredient Identifier
- QZU4H47A3S
- Background
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the pa...
- Indication
Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with cobicistat and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at l...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women
- Conditions
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 24
- Registration Number
- NCT00869960
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
- Conditions
- Interventions
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2016-01-13
- Target Recruit Count
- 334
- Registration Number
- NCT00851799
- Locations
- 🇺🇸
Harbor - UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Northwestern University CRS (2701), Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States
Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 185
- Registration Number
- NCT00833482
- Locations
- 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇳🇱Local Institution, Nijmegen, Netherlands
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
- Conditions
- Interventions
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Yale University
- Target Recruit Count
- 60
- Registration Number
- NCT00814879
- Locations
- 🇺🇸
Saint Raphael Healthcare System, New Haven, Connecticut, United States
🇺🇸Waterbury Hospital, Waterbury, Connecticut, United States
🇺🇸VA CT Healthcare Systems, West Haven, Connecticut, United States
Comparative Study of Three NNRTI-Sparing HAART Regimens
- Conditions
- Interventions
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2014-09-05
- Target Recruit Count
- 1814
- Registration Number
- NCT00811954
- Locations
- 🇺🇸
The Ponce de Leon Center CRS, Atlanta, Georgia, United States
🇺🇸The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
🇺🇸Trinity Health and Wellness Center, Dallas, Texas, United States
Phase IIB Pilot of Atazanavir + Raltegravir
- Conditions
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2012-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 167
- Registration Number
- NCT00768989
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇫🇷Local Institution, Paris Cedex 20, France
🇺🇸Yale University School Of Medicine, New Haven, Connecticut, United States
Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
- Conditions
- Interventions
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Tibotec, Inc
- Target Recruit Count
- 68
- Registration Number
- NCT00757783
Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors
- Conditions
- Interventions
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 30
- Registration Number
- NCT00720590
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada
- Conditions
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2011-12-22
- Target Recruit Count
- 35
- Registration Number
- NCT00528060
- Locations
- 🇫🇷
Hopital du Kremlin Bicêtre Service de médecine interne, Kremlin Bicëtre, France
🇫🇷Hopital Bichat CIC, Paris cedex 18, France
DDI HV (ATV - Merck)
- Conditions
- Interventions
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2010-02-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT00518297
- Locations
- 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.